Tirzepatide, the active ingredient in Eli Lilly’s Mounjaro and Zepbound, leads to more weight loss than semaglutide, the active ingredient in Novo Nordisk’s Ozempic and Wegovy, new research suggests.

The Odyssey Ai-One Cruiser line is built on the now-familiar AI-One platform, but with head weights and shapes designed to offer extra stability and, in some cases, slightly larger head sizes. The ...

The battle for market share between the two leaders in the booming obesity drug sector has a new data point decidedly in favor of Eli Lilly. The Lilly drug Zepbound has topped Novo Nordisk’s Wegovy in ...

The most common adverse events reported with both treatments were mild to moderate gastrointestinal-related side effects. Tirzepatide treatment led to a 47% greater relative reduction in weight ...

Companies will perform clinical trials of drugs, but they aren't likely going to be directly comparable. The patient population may be slightly different and the time period may not be the same, and ...